Concord Biotech Limited has announced the closure of its trading window starting October 1, 2026. This restriction applies to the equity shares of the company and will remain in effect until the expiry of 48 hours following the declaration of the unaudited financial results for the quarter and half year ended September 30, 2026.

The decision is made pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time. It also aligns with the company's internal Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders.

Restrictions on designated persons

All Designated Persons of the company and their immediate relatives have been advised not to trade in the securities of Concord Biotech during the specified closure period. This measure ensures compliance with regulatory standards regarding insider trading during sensitive financial reporting periods.

The company stated that it will inform the stock exchanges in due course about the date of the Board Meeting at which the unaudited financial results for the quarter and half year ended September 30, 2026, will be considered, approved, and taken on record.

Concord Biotech Limited has commenced the shareholder approval process for its proposed 1:1 bonus issue and increase in authorised share capital to ₹22 crore. Remote e-voting for the resolutions begins on September 25, 2026, and concludes on October 24, 2026.

The company notified stock exchanges on September 24, 2026, regarding the dispatch of the Postal Ballot Notice dated September 23, 2026. The notice seeks member approval for two ordinary resolutions: increasing authorised capital and issuing bonus shares by capitalising the securities premium account.

Bonus Issue Details

The Board approved the issuance of bonus equity shares in the proportion of 1:1, meaning one fully paid-up equity share of ₹1 each for every one existing equity share held by shareholders as on the record date. This issuance will be executed by capitalising the share premium account.

Authorised Capital Increase

Concurrently, the Board approved an increase in the Company’s authorised share capital from ₹11 crore to ₹22 crore. This involves the creation of an additional 11,00,00,000 equity shares of ₹1 each, ranking pari passu with existing shares. Consequently, Clause V of the Memorandum of Association will be amended to reflect the new authorised capital structure.

Voting Timeline and Eligibility

Shareholders whose names appear in the Register of Members as on September 18, 2026, are eligible to vote. The remote e-voting period is scheduled as follows:

Voting rights are proportional to the amount paid up on the total number of equity shares held as on the cut-off date. Institutional members must send board resolutions authorising their representatives to vote to the scrutinizer, Mr. Ashish Shah of M/s. Ashish Shah & Associates.

Regulatory Compliance

The intimation was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both the National Stock Exchange of India Limited and BSE Limited regarding the scheduled meeting and its outcomes.

Paritosh Trivedi, Company Secretary & Compliance Officer, signed the disclosure on September 23, 2026.